Cost-effectiveness of neonatal screening for Duchenne muscular dystrophy—How does this compare to existing neonatal screening for metabolic disorders?

1993 ◽  
Vol 37 (4) ◽  
pp. 541-547 ◽  
Author(s):  
T. Rosenberg ◽  
H.K. Jacobs ◽  
R. Thompson ◽  
J.M. Horne
The Lancet ◽  
1978 ◽  
Vol 312 (8099) ◽  
pp. 1100 ◽  
Author(s):  
CH. Dellamonica ◽  
J.M. Robert ◽  
J. Cotte ◽  
C. Collombel ◽  
C. Dorche

1993 ◽  
Vol 30 (8) ◽  
pp. 670-674 ◽  
Author(s):  
E Hildes ◽  
H K Jacobs ◽  
A Cameron ◽  
S S Seshia ◽  
F Booth ◽  
...  

The Lancet ◽  
1989 ◽  
Vol 333 (8639) ◽  
pp. 669 ◽  
Author(s):  
H Plauchu ◽  
C Dorche ◽  
M.P Cordier ◽  
P Guibaud ◽  
J.M Robert

2006 ◽  
pp. 192-200
Author(s):  
David M. B. Hall ◽  
David Elliman

Chapter 9 cover phenylketonuria and hypothyroidism, other metabolic disorders, cystic fibrosis, Duchenne muscular dystrophy, urine analysis and urine infections, reflux, haemoglobinopathies, liver disease in infancy, hypercholesterolaemia, lead poisoning, neuroblastoma, and coeliac disease.


1983 ◽  
Vol 29 (1) ◽  
pp. 161-163 ◽  
Author(s):  
C Dellamonica ◽  
C Collombel ◽  
J Cotte ◽  
P Addis

Abstract Neonatal screening for Duchenne-type muscular dystrophy is greatly simplified by use of a new bioluminescence procedure for creatine kinase. The blood of newborn myopathic children consistently showed increased activity. The improved method permits the analysis from a dried sample of whole blood spotted on filter paper; it shows high correlation with existing procedures and is highly specific and precise. The use of the improved method in a screening program involving 158 000 newborns is reviewed. We find a prevalence of 1/5929 living eighth-day boys.


The Lancet ◽  
1988 ◽  
Vol 332 (8608) ◽  
pp. 425-427 ◽  
Author(s):  
C.R. Greenberg ◽  
H.K. Jacobs ◽  
E. Nylen ◽  
M. Rohringer ◽  
N. Averill ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document